Bright minds biosciences announces changes to its executive leadership team, marking the transition to a development organization

Vancouver, british columbia, june 27, 2022 (globe newswire) -- bright minds biosciences (“bright minds,” “bmb” or the “company”) (nasdaq: drug) (cse: drug), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that dr. alan kozikowski will no longer serve in the role of chief scientific officer.
DRUG Ratings Summary
DRUG Quant Ranking